Eureka Therapeutics

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in the Bay Area. It develops transformative technology platforms that can access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies. The company operates two proprietary platforms, E-ALPHA and ARTEMIS, and pursues a strategy of developing multiple potential treatment options for patients by cultivating a deeper understanding of each type of cancer and leveraging its technology platforms.

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in the Bay Area. Its mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer. The company's approach to fighting solid tumors is to develop multiple potential treatment options for patients by cultivating a deeper understanding of each type of cancer and leveraging its cutting-edge technology platforms. Its innovation journey is presented on its website in phases covering 2006–2012, 2013–2018, and 2019–current.

Clinical-stage biopharmaceutical company developing T-cell therapies for solid tumors.

• E-ALPHA

  A proprietary platform leveraging high-throughput screening to develop cancer-specific antibodies.

• ARTEMIS

  A proprietary platform harnessing the evolutionary power of T cells to fight cancer.

• 2020.07.20

  Reported2020.07.20

  JW Therapeutics announces acquisition of Syracuse Biopharma[3]JW Therapeutics宣布收购Syracuse Biopharmabiospace.com

  JW Therapeutics announced its acquisition of Syracuse Biopharma (Hong Kong) Limited. The acquisition includes a license for Eureka Therapeutics’ ARTEMIS antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries; transaction terms were not disclosed.

Read more

1. 1Eurekaeurekatherapeutics.com
2. 2About - Eurekaeurekatherapeutics.com
3. 3JW Therapeutics宣布收购Syracuse Biopharmabiospace.com